Association of Cancer Care Centers的动态

Thrilled to spotlight the impressive work of Dr. Kimmie Ng, MD, MPH, a leading figure in gastrointestinal oncology and a leader in the fight against young-onset colorectal cancer. As Associate Chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, Dr. Ng's dedication to patient care, research, and advocacy is truly inspiring. With her extensive background in translational research, Dr. Ng explores the depths of molecular predictors for survival, the impact of diet, and the elusive causes of colorectal cancer in younger individuals. Read Full Article Here:https://bit.ly/43zXxBE Follow us for Daily Stories in the Medical Space ??Courtesy of https://bit.ly/3PHZd6G #DrKimmieNg #InspiringLeadership #ColorectalCancer #GastrointestinalOncology #YoungOnsetCancer #InspiringJourneys #CancerAwareness #AdvancingPatientCare #Oncology #FightAgainstCancer

Bowel cancer, also known as colorectal cancer, is the third most common cancer worldwide, and the second leading cause of cancer-related deaths globally.? ? For Colorectal Cancer Awareness Month, we interviewed Professor Pedro Pimentel Nunes, Gastroenterology and Clinical Research Medical Director, Unilabs Portugal to find out why early detection is crucial in improving patient outcomes — and how a combination of colonoscopy, coupled with AI is improving detection and enabling the removal of growths before they progress into cancer.? ?? Our interview with Professor Nunes includes insights on screening methods, advancements in research, and patient risk factors:? ???? https://lnkd.in/eaC2iQ6x? ?? #ColorectalCancerAwareness #Oncology #Healthcare?

I am constantly intrigued by innovative approaches that enhance patient outcomes. Recently, I came across a compelling research paper highlighting the efficacy of combining Transarterial Chemoembolization (TACE) with Radiofrequency Ablation (RFA) in treating intermediate stage Hepatocellular Carcinoma (HCC). The study, published in BMC Cancer, underscores how this dual approach not only delays tumor progression but also extends overall survival among patients with BCLC stage B HCC. By leveraging TACE to reduce tumor burden followed by RFA for precise ablation, clinicians can potentially achieve better local control and improved long-term prognosis compared to monotherapy. Moreover, the findings emphasize the importance of personalized treatment strategies tailored to individual patient profiles, considering factors like tumor size and number. This tailored approach underscores a paradigm shift towards more effective management of HCC, offering new hope to patients facing this challenging diagnosis. For those interested in the detailed insights of this study, you can access the full article here: https://lnkd.in/eC4UcUng #MedicalResearch #HepatocellularCarcinoma #Oncology #StudentPerspective #MedicalInnovation

Guiding #CancerTherapy: How #PSMAPET is Enhancing Personalized Treatment Approaches PSMA PET scans are revolutionizing #prostate cancer care, offering unprecedented precision in diagnosis and treatment. By targeting the PSMA protein on prostate cancer cells, these scans provide highly detailed images for earlier detection and accurate staging. The real power of PSMA PET lies in its ability to guide therapy decisions with pinpoint accuracy. Oncologists can determine the exact extent of cancer spread, crucial for planning effective treatments while sparing healthy tissue. PSMA PET is also central to the #theranostics approach, combining #diagnosticimaging with targeted #radiotherapy, enhancing treatment efficacy, and opening new avenues for resistant cancers. Explore the future of #oncology with PSMA PET, bringing hope and better outcomes for patients worldwide. For more insights, check out the latest edition of Le Patient magazine: https://lnkd.in/euQrUYj9 #PrecisionMedicine #PSMAPET #ProstateCancer #CancerCare #OncologyInnovation #HealthcareTech #CancerTreatment #MedicalAdvancements #EarlyDetection #PatientCare

Early detection and treatment are imperative for improving breast cancer survival rates. The emergence of radiogenomics within precision medicine is a promising avenue. This article by a team of authors, including Fortrea’s Kamal Saini, MD, Executive Medical Director, delves into the theoretical underpinnings and explores practical applications in the diagnosis, management and treatment of breast cancer. https://lnkd.in/eBbYbtbK

??Highlights from ESMO 2024! Dr Dieter Stevens, thoracic oncologist at University Hospital Ghent, shares key insights from non-metastatic NSCLC studies: - CheckMate 77T: Neoadjuvant immunotherapy improves EFS and pCR rates in early-stage NSCLC. - ctDNA as a Biomarker: ctDNA clearance may predict treatment response in NSCLC. - AI in Oncology: AI models offer new possibilities in tracking disease progression and predicting risks in lung cancer. Discover these updates.?? For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #LungCancer #Oncology #CancerResearch #ClinicalTrials?

The American Society of Clinical Oncology (ASCO) Annual Meeting, one of the premier conferences in oncology, took place from May 31 to June 4 in Chicago, Illinois. This event brought together oncologists, researchers, and healthcare professionals to discuss the latest advancements in cancer research and patient care. In this video,?Dr. Minesh Mehta, a radiation oncologist at Miami Cancer Institute, shared insights on ‘Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.‘ https://lnkd.in/e2ZiT6zJ #OncoDaily #Oncology #Cancer #Health #Medicine #ASCO24 #CancerCare

??Highlights from ESMO 2024! Prof Dr Karen Geboes, digestive oncologist at University Hospital Ghent, presents key findings from trials in upper digestive cancers: - TOPGEAR Trial: Pre-operative chemoradiation shows no survival benefit in gastric cancer. - MOONLIGHT Study: FLOT plus nivolumab shows potential in PD-L1 positive patients. - KEYNOTE-811: Pembrolizumab adds a two-month survival benefit in HER2-positive gastric cancer. - DESTINY GASTRIC-03: Trastuzumab deruxtecan plus chemotherapy outperforms monotherapy. Discover these updates.?? For all ESMO 2024 videos, find the link in the comments!? #MediMix #ESMO2024 #GICancer #Oncology #CancerResearch #ClinicalTrials

Attention pathologists, oncologists, laboratory professionals, and patient advocacy groups: The CAP, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (AMP) invite all to contribute to the open comment period for the updated molecular testing #guidelines for lung cancer. Developed by an expert panel through a systematic literature review, these draft recommendations aim to enhance clinical practice and patient outcomes. Your expertise is crucial in ensuring these recommendations are comprehensive and effective. Provide your feedback to help enhance patient care—Comment period closes 9/12. https://shorturl.at/0Fp13 #Oncology #MolecularTesting #LungCancerResearch #MolPath #CAPguideline

Breast and lung cancers are two of the most common forms of cancer in Asia. Much more can be done to improve diagnostics and treatment mechanisms to improve patient outcomes. This, however, cannot be done in isolation. Together with GE HealthCare, we have brought together our skillsets and expertise to advance oncology care access across Southeast Asia, Korea, Australia, and New Zealand. Leveraging GE HealthCare’s oncology care pathway with our advanced expertise in diagnostics, pathology lab solutions, and digital pathology, we will provide more accurate and comprehensive diagnostic solutions across the oncology care continuum, working towards creating healthier communities. Read more about this partnership here: https://lnkd.in/g8kmb8uK Thilo Brenner | Chris Chiam | Reuben Cherian | Amy Lee | Dr Ritoj Goswami | Dr. Anthony Lawrence | Junaidah Dahlan #GEHealthCare #RocheDiagnostics #Oncology #PrecisionCare #HealthcareInnovation #DigitalPathology